| Literature DB >> 30128074 |
Suchitra Ravula1, Brad M Savall1, Nyantsz Wu1, Brian Lord1, Kevin Coe1, Kai Wang1, Mark Seierstad1, Devin M Swanson1, Jeannie Ziff1, Minh Nguyen1, Perry Leung1, Ray Rynberg1, David La1, Daniel J Pippel1, Tatiana Koudriakova1, Timothy W Lovenberg1, Nicholas I Carruthers1, Michael P Maher1, Michael K Ameriks1.
Abstract
Glutamate mediates fast excitatory neurotransmission via ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The trafficking and gating properties of AMPA receptors (AMPARs) can be amplified by transmembrane AMPAR regulatory proteins (TARPs), which are often expressed in localized brain regions. Herein, we describe the discovery, lead optimization, and preclinical characterization of 5-arylbenzimidazolone and oxindole-based negative modulators of AMPARs associated with TARP γ-8, the primary TARP found in hippocampus. High-throughput screen lead 4 was optimized for potency and brain penetration to provide benzimidazolone 3, JNJ-55511118.1 Replacement of the benzimidazolone core in 3 with an oxindole mitigated reactive metabolite formation and led to the identification of 18 (GluA1/γ-8 pIC50 = 9.7). Following oral dosing in rats, 18 demonstrated robust target engagement in hippocampus as assessed by ex vivo autoradiography (ED50 = 0.6 mg/kg, plasma EC50 = 9 ng/mL).Entities:
Year: 2018 PMID: 30128074 PMCID: PMC6088354 DOI: 10.1021/acsmedchemlett.8b00215
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345